Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-11-14
1996-01-09
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 64, 514 80, 514381, 514382, 514418, 548250, 548251, 548252, 548253, 548405, 548412, 548454, 548484, 548485, 548486, 548490, 548491, 548492, 548503, 548504, 548506, 548507, 548511, A61K 3140, C07D20904
Patent
active
054829607
ABSTRACT:
Novel indole and indoline nonpeptide antagonists of endothelin I are described, as well as novel intermediates used in their preparation, methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure and subarachnoid hemorrhage.
REFERENCES:
patent: 5132319 (1992-07-01), Girard et al.
Watanabe, T., et al., "Endothelin in Myocardial Infarction," Nature (Lond.) 1990;344:114.
Margulies, K. B., et al., "Increased Endothelin in Experimental Heart Failure," Circulation 1990;82:2226.
Kon, V., et al., "Glomerular Actions of Endothelin in Vivo," J. Clin. Invest. 1989;83:1762.
Perico, N., et al., "Endothelin Mediates the Renal Vasoconstriction Induced by Cyclosporine in the Rat," J. Am. Soc. Nephrol. 1990;1:76.
Koshi, T., et al., "Inhibition of Endothelin (ET)-1 and ET-2-Induced Vasoconstriction by Anti-ET-1 Monoclonal Antibody," Chem. Pharma. Bull. 1991;39:1295.
Miyamori, I., et al., "Systemic and Regional Effects of Endothelin in Rabbits: Effects of Endothelin Antibody," Clin. Exp. Pharmacol. Physiol. 1990;17:691.
Ohno, A. "Effects of Endothelin-Specific Antibodies and Endothelin in Spontaneously Hypertensive Rats," J. Tokyo Women's Med. Coll. 1991;61:951.
Lerman, A., et al., "Endothelin has Biological Actions at Pathophysiological Concentrations," Circulation 1991;83:1808.
Rodeheffer, R. J., et al., "Circulating Plasma Endothelin Correlates With the Severity of Congestive Heart Failure in Humans," Am. J. Hypertension 1991;4:9A.
Arai, H., et al., Nature 1990;348:730.
Sakurai, T., et al., Nature 1990;348:732.
Lin, H. Y., et al., Proc. Natl. Acad. Sci. 1991;88:3185.
Sakamoto, A., et al., Biochem. Biophys. Res. Chem. 1991;178:656.
Hosoda, K., et al., FEBS Lett. 1991;287:23.
Takayanagi, R., et al., FEBS Lett. 1991;282:103.
Panek, R. L., et al., Biochem. Biophys. Res. Commun. 1992;183 (2) :566.
Saeki, T., et al., Biochem. Biophys. Res. Commun. 1991;179:286.
Nakagawa, K. et al., Nippon Hifuka Gakkai Zasshi 1990;100:1453-1456.
Noguchi, et al., Am. Rev. Respir. Dis. 1992;145 (4 Part 2):A858.
Clark B. A., et al., Am. J. Obstet. Gynecol. 1992;166:962-968.
Pittett J., et al,. Ann Surg. 1991;213 (3):262.
Gandhi C. B., et al., Journal of Biological Chemistry 1990;265 (29):17432.
Collier A., et al., Diabetes Care 1992;15 (8):1038.
Basil M. K., et al., J. Hypertension 1992;10 (Suppl 4):S49.
Han S. -P., et al., Life Sci. 1990;46:767.
Nikolov R. K., et al., Drugs of Today 1992;28 (5):303-310.
A. Lerman, et al., New England J. Med. 1991;325:997-1001.
K. Kanno, et al., J. Amer. Med. Assoc. 1990;264-2868.
M. R. Zamora, et al., Lancet 1990;336:1144-1147.
A. Tahara, et al., Metab. Clin. Exp. 1991;40:1235-1237.
Stewart, D. J., et al, Ann. Internal Medicine 1991;114:464-469.
Yasuda, M., et al., Amer. Heart J. 1990;119:801-806.
Stewart, J. T., et al., Br. Heart J. 1991;66:7-9.
Lopez-Farre, A., et al., J. Physiology 1991;444:513-522.
Stockenhuber, F., et al., Clin. Sci. (Lond.) 1992;82:255-258.
Mirua, S., et al., Digestion 1991;48:163-172.
Masuda, E., et al., Am. J. Physiol. 1992;262:G785-G790.
Murch, S. H., et al., Lancet 1992;339:381-384.
Clozel, M., et al., "Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist," Nature, 1993:365:759.
Clozel, M. and Watanabe, H., Life Sci. 1993;52:825-834.
Stein P. D., et al., "The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ET.sub.A Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide," J. Med. Chem., 1994;37:329-331.
Elliott, J. D., et al., J. Med. Chem., 1994; 37: 1553-7.
Douglas, S. A., et al., Circ. Res., 1994; 75:190-7.
CA 110: 57508r Preparation . . . Biosynthesis. Gillard et al., p. 674, 1989.
CA 115: 71393j Preparation . . . Agents. Gubin et al., p. 774, 1991.
CA 116: 255478t Preparation . . . Inhibitors. Gillard et al., p. 775, 1992.
CA 117: 191685u Preparation . . . Biosynthesis. Girard et al., p. 784, 1992.
CA 119: 95328 Indoles . . . Transcriptase. Williams et al. 1993.
Berryman Kent A.
Bunker Amy M.
Doherty Annette M.
Edmunds Jeremy J.
Anderson Elizabeth M.
McKane Joseph K.
Warner-Lambert & Company
LandOfFree
Nonpeptide endothelin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nonpeptide endothelin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nonpeptide endothelin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1303381